首页 | 本学科首页   官方微博 | 高级检索  
     


Venous thromboembolism in pediatric nephrotic syndrome
Authors:Bryce A. Kerlin  Kellie Haworth  William E. Smoyer
Affiliation:1. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
2. Center for Clinical and Translational Research, The Research Institute at Nationwide Children’s, 700 Children’s Dr., W325, Columbus, OH, 43205-2696, USA
3. Division of Hematology/Oncology/Bone Marrow Transplantation, Nationwide Children’s Hospital, Columbus, OH, USA
4. Division of Nephrology, Nationwide Children’s Hospital, Columbus, OH, USA
Abstract:Childhood nephrotic syndrome (NS) is one of the most common pediatric kidney diseases, with an incidence of 2–7 per 100,000. Venous thromboembolism (VTE) is associated with significant morbidity and mortality, and occurs in ~3 % of children with NS, though incidence approaches 25 % in high-risk groups. VTE etiology is multifactorial, with disease-associated coagulopathy thought to be a significant contributor. Other risks include age, disease severity, and treatment-related hazards, such as the presence of central venous catheters. Non-pharmacologic preventive measures such as ambulation and compression stockings are recommended for patients with identified VTE risks. Central venous catheters should be avoided whenever possible. Symptoms of VTE include venous catheter dysfunction, unilateral extremity symptoms, respiratory compromise, flank pain, and gross hematuria. When VTE is suspected, confirmatory imaging studies should be obtained, followed by appropriate laboratory evaluation and treatment. Therapeutic goals include limiting thrombus growth, extension, and embolization by early institution of anticoagulant therapy. Anticoagulation is recommended for a minimum of 3 months, but should be continued until NS remission is achieved. Further studies are necessary to identify VTE-risk biomarkers and optimal therapeutic regimens. Observational cohort studies are needed to identify VTE-risk groups who may benefit from thromboprophylaxis and to define disease-specific treatment algorithms.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号